NCT04952987

Dry Eye Management With 3% Diquafosol Before and After Cataract Surgery

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 50 (estimated)
• Sponsor: Mun Wai Lee · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The objective of this study is to evaluate the efficacy of Diquafosol 3% in the management of dry eyes before and after cataract surgery. Patients with pre-existing dry eyes and planned for cataract surgery will be started on Diquafosol eyedrops prior to surgery and treatment will be continued after cataract surgery. Eligible patients will undergo evaluation of dry eye at baseline and subsequently started on treatment with Diquafosol for the duration of 4 weeks before surgery. Further evaluations will be conducted on the day of surgery and at designated time points during and up to 12 weeks after surgery.

Detailed description

Title: Dry Eye Management with 3% Diquafosol Before and After Cataract Surgery Setting: LEC Eye Centre, Ipoh, Malaysia Background: Dry eye disease and cataract are two conditions which have been known to increase in incidence with age. Dry eye disease can also be further exacerbated by cataract surgery. Diquafosol (Diquas) is a P2Y2 receptor agonist which improves mucin and tear secretion and is a 'first in class' therapeutic option which has been shown repeatedly to be efficacious in dry eye management. Objective: To evaluate the efficacy of Diquafosol for dry eye management in patients with pre-existing dry eye disease before and after cataract surgery Design: Observational case series in a private ophthalmic health facility Study Plan: Eligible patients will have treatment with Diquas for 4 weeks prior to undergoing cataract surgery. Preoperative clinical evaluation will include documentation of severity of signs and symptoms of dry eye and this will be carried out at baseline, immediately before surgery and subsequently at Week 4 and Week 12.

Conditions

• Dry Eye

Interventions

Type	Name	Description
DRUG	Diquafosol	Diquafosol (Diquas) is a P2Y2 receptor agonist which improves mucin and tear secretion

Timeline

• Start date: 2021-01-01
• Primary completion: 2021-12-30
• Completion: 2021-12-30
• First posted: 2021-07-07
• Last updated: 2021-07-07

Locations

1 site across 1 country: Malaysia